Long-Term Mortality and Morbidity Related to Congestive Heart Failure with Reduced Ejection Fraction (CHFrEF) in Palestinian Patients Maintained on Submaximal Sacubitril/Valsartan Doses: A Pilot Study

Figure 1

Graphs show changes in the LVEF in relation to different accumulative medication doses. For patients on 50 mg of sacubitril/valsartan daily, an average of and was achieved. For patients on 100 mg daily, an average of and was achieved. Finally, for those receiving 200 mg daily, an average of and was obtained. In all cases, the value was statistically significant (i.e., below the 0.05 cut-off).